Precautionary class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, issued

News
Article

A precautionary recall of Zaditen eye drops is issued due to potential microbial contamination, affecting batch 4V64. No adverse events reported.

Viersen, Germany - December 1. 2021: Closeup of mobile phone screen with logo lettering of UK MHRA agency, serum vials and syringe background (Image credit: ©Ralf/AdobeStock)

(Image credit: ©Ralf/AdobeStock)

A class 2 medicines recall of Zaditen 0.25 mg/ml, eye drops, solution, has been issued after Laboratoires Théa notified the Medicines and Healthcare products Regulatory Agency (MHRA) of an event during manufacturing that may increase the risk of microbial contamination in the product.1 This recall is precautionary and there are currently no adverse events reported.

Batch number 4V64 of Zaditen 0.25 mg/ml, eye drops, solution, was first distributed January 27, 2025, and has an expiration date of September 30, 2026.

Due to the recall, healthcare professionals are advised from the MHRA to stop supplying the batch immediately and to quarantine all stock and return it to the supplier it was received by. A confirmed 11,360 packs of the affected batch have been distributed, according to Thea Pharmaceuticals. At the time of this article, there are no reported adverse events or product quality complaints received.

For patients, the MHRA said no further action is required, “as this is a Pharmacy and Wholesaler level recall related to a specific batch of Zaditen 0.25 mg/ml, eye drops, solution,” according to a press release. Should any suspected adverse reactions arise, they can be reported via the MHRA Yellow Card scheme.1

For stock control enquiries:1

  • For pharmacies supplied by a wholesaler, returns should be made via the wholesaler.
  • For wholesalers, contact Mawdsleys PreWholesaler (MPS) customer services via email: customer.services@mpwpharma.co.uk.
  • For healthcare establishments, arrange local destruction and make a claim through MPS via email: customer.services@mpwpharma.co.uk.

For more information of medical information, call 0345 521 1290 (option 3) or email thea-pharma@medinformation.co.uk.

Reference:
1. Class 2 Medicines Recall: Zaditen 0.25 mg/ml, eye drops, solution, Laboratoires Théa EL(25)A/34. GOV.UK. Published July 7, 2025. Accessed July 8, 2025. https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-zaditen-0-dot-25-mg-slash-ml-eye-drops-solution-laboratoires-thea-el-25-a-slash-34

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.